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Abstract: Hepatic encephalopathy is a common neuropsychiatric abnormality, which compli-
cates the course of patients with liver disease. It was probably first described by Hippocrates over 
2000 years ago, who said that “those whose madness arises from phlegm are quiet and neither 
shout nor make a disturbance, while those whose madness arises from bile shout, play tricks 
and will not keep still, but are always up to some mischief ”. He was presumably describing the 
differences between patients with pneumonia and acute liver failure. Despite the fact that the syn-
drome was probably first recognized thousands of years ago, the exact pathogenesis still remains 
unclear. Furthermore, a precise definition of the syndrome is lacking, as are definitive methods of 
diagnosing this condition. It is important as both patients with cirrhosis and the general population 
with whom they interact may be affected as a consequence. At a minimum, the individual may be 
affected by impaired quality of life, impaired ability to work, and slowed reaction times, which 
are relevant to the population at large if affected individuals operate heavy machinery or drive a 
car. Pathogenic mechanisms, diagnostic tools, and treatment options are discussed.
Keywords: hepatic encephalopathy, cirrhosis, ammonia, pathology, treatment, rifaximin, 
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Background
Hepatic encephalopathy (HE) is a complex, reversible neuropsychiatric syndrome, 
complicating the course of liver disease. In recent guidelines published jointly by the 
European and American Associations for the Study of the Liver, HE was defined as 
“brain dysfunction caused by liver insufficiency or portal systemic shunting”.1,2 Despite 
the fact that the syndrome was probably recognized thousands of years ago, the exact 
pathogenesis remains unclear.3
The pathogenesis is thought to be attributable to both neurochemical and neu-
rophysiological disorders of the brain.4 The essentially reversible nature suggests a 
metabolic cause. The broad spectrum of cerebral disturbance is likely to be a reflection 
of the range of metabolic disturbances responsible for the syndrome, rather than one 
causal abnormality.
One of the central factors contributing to HE in cirrhosis is unfiltered blood from the 
portal system reaching the brain. Neuropathologically, the most frequently described 
change is to astrocytes, which undergo cell swelling.5 The morphological change seen 
is known as Alzheimer type II astrocytosis. However, neurons remain structurally 
normal. Theories on pathogenesis of HE are outlined in Table 1.
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Gut-derived neurotoxins
Ammonia has been the most studied gut-derived neurotoxin, 
produced from the breakdown of proteins and amino acids. 
Ammonia is produced by the gastrointestinal tract in two ways: 
by direct ammonia liberation from breakdown products of 
dietary protein and metabolism of circulating glutamine (GLN) 
and by the gut microbiome acting upon urea and ingested food. 
Concentrations of ammonia are kept relatively constant in the 
blood by efficient detoxification processes, involving hepatic 
production of urea and synthesis of GLN from glutamate (GLU) 
by the action of glutamine synthetase (GS), which is located in 
the liver, muscle, and brain.6 Hyperammonemia is commonly 
seen in chronic liver disease, as are high levels of circulating 
endotoxins, as the liver fails to detoxify the portal circulation 
draining the intestines, which are heavily colonized by meta-
bolically active bacteria, or else because the portal blood sup-
ply bypasses the liver through the development of a collateral 
circulation in the presence of portal hypertension.
The first suggestion that ammonia may be involved in 
HE was in 1893 by investigators from Pavlov’s group.7 
A rise in arterial blood ammonia in dogs was associated with 
behavioral disturbances after high protein meals.8 Fifty years 
later, Gabuzda et al inadvertently produced HE in chronic 
liver disease patients, treated with ion-exchange resins to 
diminish ascites.9 The resins absorbed sodium, but released 
ammonium ions, bringing about HE.
More recent animal studies using portacaval shunts 
showed blood and brain ammonia concentrations to be 
increased two- and three folds, respectively.10 Primary 
cultured astrocytes exposed to ammonia have been shown 
to develop features of Alzheimer type II astrocytosis seen 
neuropathologically in human beings.11
Short- and medium-chain fatty acids are increased in the 
blood of patients with HE.12 These fatty acids produce coma 
in animal models and possibly interfere with ureagenesis.13 
Nevertheless, these agents have been given to patients without 
any adverse consequences.14
Amino acid disturbances have been observed in HE 
patients, typically increased aromatic amines and decreased 
or normal levels of branched-chain amino acids (BCAAs).15,16 
Low plasma concentrations of BCAAs are a result of 
increased use by muscle, heart, kidney, and adipose tissue 
as an energy source,17 since alternatives such as glucose and 
ketone bodies are reduced in liver disease. Hyperammonemia 
results in increased brain uptake of aromatic acids, including 
tryptophan, the precursor of the neurotransmitter, serotonin. 
Tryptophan’s increased availability leads to altered serotonin 
synthesis, increasing neuroinhibition.18
Cerebral neurotransmission
GLU is the predominant excitatory neurotransmitter in 
the brain. In HE, astrocytes play an important role in 
detoxification of ammonia through conversion of GLU to 
GLN. Astrocytic GLU reuptake mechanisms may become 
impaired; thereby increasing extracellular concentrations 
of GLU.19 Furthermore, GLU binding sites appear to be 
downregulated on postsynaptic neurons. This, therefore, con-
tributes to decreased neuroexcitatory activity20 and increased 
cerebral GLN.21
γ-Aminobutyric acid (GABA) is the predominant inhibi-
tory neurotransmitter in the brain,22 binding to specific GABA 
receptors, which are part of larger receptor complexes, acti-
vated by benzodiazepines and barbiturates. For the most part, 
GABA is synthesized by gut bacteria and would normally 
enter the portal vein to be metabolized by the liver. In cirrhosis, 
blood bypasses the liver by collaterals and enters the systemic 
circulation. Increased plasma levels of GABA have been 
observed in patients with HE.23 However, autopsied brain tis-
sue from HE patients did not support GABA involvement.24
Translocator proteins (TSPOs), formerly known as periph-
eral benzodiazepine binding sites, may play an important role 
in neuroinhibition. TSPOs are 18 kDa proteins, located on the 
outer mitochondrial membrane of astrocytes, and facilitate cho-
lesterol ingress into mitochondria, among other roles.25 TSPOs 
are widely distributed throughout the body and are also present 
in microglia.26 TSPOs are upregulated by ammonia27 and have 
been shown to be present in increased density in autopsied 
brains of HE patients.28 TSPO upregulation promotes synthesis 
of neurosteroids, such as tetrahydroprogesterone and tetrahy-
drodeoxycorticosterone, which are potent agonists of GABA
A
 
receptors (Figure 1). In vivo positron emission tomography 
(PET) studies support the hypothesis that TSPOs could play 
an active role in impaired brain functioning in HE.29
Table 1 Theories for pathogenesis of He
Location of alteration Suggested mechanism
Gut-derived neurotoxins Ammonia
Short- and medium-chain fatty acids
Amino acid disturbances
Cerebral neurotransmission GLU
GABA
Peripheral benzodiazepine binding sites
Cerebral energy metabolism Cerebral blood flow changes
Alteration in cerebral glucose metabolism
Blood–brain barrier Functional changes
Low-grade cerebral edema Astrocyte swelling
Abbreviations: He, hepatic encephalopathy; GLU, glutamate; GABA, γ-aminobutyric 
acid.
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Inflammation
It is frequently observed that cirrhosis patients with active 
infections may exhibit HE, leading several investigators to 
consider a direct link between HE and inflammation. One 
group medically induced hyperammonemia, using amino acid 
solution, in a group of stable cirrhosis patients.30 Patients with 
abnormal psychometric performance had more markedly 
elevated inflammatory markers (white cell count, neutrophil 
count, C-reactive protein, nitrate/nitrite, and interleukin 
[IL]-6). Psychometric performance deteriorated in 44.8% 
of patients with the amino acid solution. In “deteriorators”, 
there was an increase in inflammatory markers, compared 
to “nondeteriorators”. Further support for this theory is pro-
vided by another group, which studied effects of alteration 
of gut flora with administration of fiber and probiotics upon 
HE patients.31 They showed that improvement in HE was 
associated with reductions in venous endotoxin and ammo-
nia levels. This is an area of increasing interest that requires 
further investigation.
Low-grade cerebral edema
It has been proposed by Häussinger et al that a major con-
tributory event to the development of HE in patients with 
chronic liver disease is an increase in astrocyte hydration 
(low-grade cerebral edema without a clinically overt increase 
in intracranial pressure).32 This may occur as a consequence of 
astrocytic ammonia uptake and subsequent detoxification by 
GS, forming GLN from GLU.10 This deamidation process is 
thought to result in accumulation of GLN within astrocytes, 
acting as a cerebral osmolyte. The cells respond by expelling 
osmolytes, myo-inositol (mI), choline (cho), and GLN, but 
the membrane transport systems are not able to keep up with 
greatly increased production of GLN. Equilibrium cannot be 
re-established and there is resultant cell swelling (Figure 2). 
Cerebral magnetic resonance spectroscopy (MRS) studies 
in vivo demonstrated reduced levels of mI and increased 
GLN and GLU (Glx).33 Additionally, benzodiazepines, 
hyponatremia, and inflammatory cytokines can induce astro-
cyte swelling in vitro, so these factors may act synergistically 
with ammonia to produce low-grade cerebral edema.32
Clinical features
Recognized clinical features of HE are listed in Table 2. The 
first widely accepted clinical grading system to attempt to 
categorize HE was described by Parsons-Smith et al.34 This 
classification system was later modified and is now known 
as either the “modified Parsons-Smith” or West Haven cri-
teria35 (Table 3).
Minimal hepatic encephalopathy
The first published work to propose that subtle mental 
changes can occur before the onset of clinically detect-
able neurological changes was by Zeegen et al in 1970.36 
They performed paper-based psychometric tests, consist-
ing of the construction of five-pointed stars and modified 
“Reitan” trail making tests on a population of patients after 
portal decompression surgery. They found that 13 out of 
34 patients (38%), without clinical signs of HE on standard 
clinical examination, had impaired performance on Reitan 
trail making tests.
Nomenclature
Subsequently, the presence of these subtle abnormalities 
has been observed by numerous investigators and gaged 
by a variety of psychometric tests.37,38 The presence of this 
abnormality was first termed subclinical or latent HE owing 
to the lack of clinical signs on examination. Subsequently, 
nomenclature was replaced by the term “minimal” HE 
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Figure 1 Schematic representation of microglial activation.
Notes: Resting microglia are spindly and spiky in appearance on electron microscopy, demonstrating low levels of constitutive PBR binding site activity (TSPO) on their 
mitochondria. when “activated”, microglia demonstrate an increased number of PBR binding sites. 11C-(R)-PK11195 is a PeT ligand that binds to PBRs.
Abbreviations: PBR, peripheral benzodiazepine receptor; TSPO, translocator protein; PeT, positron emission tomography; TNF-α, tumor necrosis factor-alpha; 
IL, interleukin; NO, nitric oxide.
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(mHE)39 (Table 4). To confuse matters further, the 2014 
AASLD/EASL guidelines also suggest an alternative 
classification considering mHE (West Haven grade 0) 
and West Haven grade 1 overt HE as “covert” HE, while 
West Haven grade 2 and above are considered as “overt” 
HE.1 However, this classification is rarely used outside the 
United States.
Clinical significance
mHE has been shown to have effects upon quality of 
life, earning potential, driving performance, and possibly 
survival.
Quality of life
Groeneweg et al used the “Sickness Impact Profile” (SIP) 
to determine the effects of mHE on patients’ “activities 
of daily living”.40 The SIP is a questionnaire assessing 
influence of the disease and treatment on daily function-
ing.41 The questionnaire consists of 136 items, grouped into 
12 scales encompassing different aspects of daily living, eg, 
sleep, eating, social interaction, and emotional behavior. They 
found that mHE patients performed significantly worse in 
every dimension of the SIP.40
Earning potential
Schomerus and Hamster selected 110 ambulatory outpatients 
with cirrhosis, who were part of a larger study undergoing 
psychometric testing.42 Of white-collar workers, 40% had 
abnormal psychometry, but only 20% were unable to continue 
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Figure 2 Hypothesis of astrocyte swelling contributing to low-grade cerebral edema.
Abbreviations: GLN, glutamine; GS, glutamine synthetase; GLU, glutamate; mI, myo-inositol; cho, choline.
Table 2 Recognized features of He
Affected domain Symptom/sign
Disturbed consciousness Reversal of sleep pattern
Drowsiness
Coma (later stages)
Personality changes Irritability
Irrational behavior
Intellectual impairment Reduced attention span
Impaired mental agility
Impaired working memory
Speech Slow
Slurred
Motor Asterixis/flapping tremor
Ataxic gait
Exaggerated tendon reflexes
Abbreviation: He, hepatic encephalopathy.
Table 3 Modified Parsons-Smith or West Haven criteria for HE
Grade 0 No abnormality detected (mHe)
Grade 1 Trivial lack of awareness
euphoria or anxiety
Shortened attention span
Impairment of addition or subtraction
Grade 2 Lethargy
Disorientation for time
Obvious personality change
Inappropriate behavior
Grade 3 Somnolence to semistupor
Responsive to stimuli
Confused
Gross disorientation, bizarre behavior
Grade 4 Coma, unable to test mental state
Note: This article was published in Gastroenterology, vol 72, Conn HO et al, 1977, 
Comparison of lactulose and neomycin in the treatment of chronic portal-systemic 
encephalopathy. A double blind controlled trial, pp573 to 583.35 Copyright elsevier 
© 2013.
Abbreviations: He, hepatic encephalopathy; mHe, minimal He.
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working, whereas 55% of blue-collar workers had abnormal 
psychometry and 60% were unable to earn their living.42
Driving ability
Wein et al measured “on-the-road” driving performance. Of 
274 consecutive patients with cirrhosis, 48 fulfilled medical 
and driving inclusion criteria, 14 of them with mHE and 34 
without mHE. The likelihood of an accident in mHE patients 
was nearly ten times higher than that of patients without 
mHE.43 Bajaj et al studied self-reported driving behavior in 
postal questionnaires. Patients with cirrhosis had a higher 
percentage of driving violations over the previous year (13%), 
previous 5 years (25%), and a higher number of accidents at 
1 year (9%) and 5 years (17%).44
Diagnosis
Despite agreement between investigators that mHE war-
rants further investigation and probably screening and 
treatment, there is little consensus as to the optimal instru-
ments with which to diagnose and monitor the condition.39 
This has a significant role in the discrepancy between 
studies, as to the prevalence of mHE, with quoted preva-
lence varying from 27% to 75% according to the battery 
of tests used, interpretation of these tests, and populations 
studied.45,46 Some studies have used just one psychometric 
test,47 whereas other studies have used up to 26 tests.38 In 
the latter case, tests needed to be spread over 2 days to 
avoid fatigue.
In response to the variability of diagnostic tests being used 
to define mHE, a consensus was reached by a working party,39 
which proposed use of a psychometric hepatic encephalopa-
thy score, based on the results of five neuropsychometric 
tests.48 They also suggested that when possible, quantitative 
neurophysiological tools, such as electroencephalography 
(EEG) with mean dominant frequency and P300 auditory 
evoked potentials, should be used.1,2
Assessment of HE
HE affects cognitive, affective/emotional, behavioral, and bio-
regulatory domains.39 Each broad domain may be subdivided 
into various components. For example, cognition may include 
evaluation of psychomotor speed, visuopraxis, attention, con-
centration, and level of consciousness.39 Overt or clinically 
apparent HE should be excluded by careful and detailed neu-
ropsychiatric examination and anamnestic enquiry. Particular 
attention should be paid to cognitive and motor function, 
ability to perform activities of daily living, and sleep–wake 
cycle abnormalities. To diagnose mHE, at least two neurop-
sychological tests from the following psychometric hepatic 
encephalopathy score system should be used:
1. Number connection test-A (NCT-A);
2. NCT-B;49
3. Block design test;
4. Digit symbol substitution test.50
The recommendation was to use a standardized battery 
including NCT-A and NCT-B, the line tracing, serial dotting, 
and digit symbol substitution tests.1,2 This battery is easy to 
apply, but reference test scores are normalized for German 
populations, so it may be necessary to adjust these for other 
patient populations. Reference ranges are now available for 
Spanish,51 Italian, and British populations.52
Paper-based tests
The theoretical advantages of paper-based tests are that they 
are easy to administer, require no sophisticated technical 
equipment, and can be performed at the bedside. However, 
in practice, they may be subject to a greater degree of 
subjectivity. Ideally, they should be performed in a quiet, 
well-lit room, under standardized conditions, which apply to 
both examiner and examinee. In practice, these conditions 
do not exist in hospital wards. The paper-and-pencil tasks 
may be affected by subjective “one-off influences”, such 
as lack of sleep, recent arguments, or hunger. Theoretically, 
Table 4 Proposed nomenclature of He
HE type Nomenclature Subcategory Subdivisions
A Associated with acute liver failure
B Associated with portal-systemic bypass and no intrinsic hepatocellular disease
C Associated with cirrhosis and portal hypertension or portal-systemic shunts episodic He Precipitated
Spontaneous
Recurrent
Persistent He Mild
Severe
Treatment dependent
mHe
Note: Copyright John Wiley & Sons © 2003. Reproduced from Ferenci P. Hepatic encephalopathy – definition, nomenclature, diagnosis, and quantification: final report of 
the working party at the 11th world Congresses of Gastroenterology, vienna, 1998. Hepatology. 2002;35(3):716–721.39
Abbreviations: He, hepatic encephalopathy; mHe, minimal He.
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the tests should also be easily interpretable, but reference 
scores should take account of education, cultural background, 
and language difficulties.
Quality of life scores
Other paper-based assessments of mHE include nonpsycho-
metric tests such as validated quality of life scores, such 
as the short form 36 health survey, SIP, and fatigue impact 
questionnaires.53–55
Computer-based psychometric 
tests
The use of computerized psychometric testing is widespread 
in both clinical research settings and for monitoring effects 
of pharmacological compounds upon cognitive function.56 
The choice of system varies from center to center, depend-
ing upon investigators’ personal experience, developmental 
input, and financial restraints. The advantages of comput-
erized systems above conventional paper-and-pencil tests 
include reproducibility of stimulus presentation, accurate 
recording of responses/reaction times, and easier to facilitate 
data analysis. Furthermore, some tests are entirely visual and 
therefore do not depend on literacy and numeracy, which can 
hamper the interpretation of paper-based tests. For example, 
the use of the Stroop test on smartphones and computer 
tablets has proven to be an easily accessible, useful tool in 
many countries of the developed world.57
Electroencephalography
The EEG detects and records patterns of electrical activ-
ity within the brain through electrodes placed in multiple 
areas on the scalp. EEG abnormalities in hepatic coma 
were described in 1950.58 One of the more constant features 
in the studies of HE is the presence of a generalized slowing 
of background EEG activity, which appears to be a constant, 
progressive, and a quantifiable finding. It is important to note 
that EEG slowing is nonspecific as it is observed in other 
metabolic and drug-induced encephalopathies.4
Evoked potentials
Evoked potentials are electrical potentials, elicited in con-
junction with sensory, motor, and cognitive events. They are 
a measure of the conduction and function of afferent path-
ways between stimulated peripheral nerves and the cortex. 
Abnormalities of visual evoked potentials, brainstem auditory 
evoked potentials, and somatosensory evoked potentials have 
been demonstrated in HE, but the sensitivity of the techniques 
appear to vary significantly between studies.4 P300 is a cog-
nitive evoked potential elicited when a subject receives an 
infrequent stimulus embedded within a group of irrelevant 
stimuli (oddball paradigm). The subject is asked to identify 
the oddball stimulus and a potential is elicited independent 
of the sensory modality being stimulated.4 The potential 
occurs ∼300 ms after the stimulus, hence its name. The P300 
appears to be useful as an investigative research tool in lower 
grades of HE.4
Critical flicker frequency
The critical flicker frequency (CFF) of an individual is the 
highest frequency in Hertz that an individual perceives the 
“flicker” of a flickering light. All frequencies above that 
threshold will be observed to be continuous. CFF is thought 
to reflect both the efficiency of the visual pathways and 
the cerebral cortex. A single study has used CFF in a well-
characterized cohort of patients with cirrhosis and healthy 
controls.59 CFF thresholds were found to be significantly 
lower in patients with mHE and overt HE than in healthy 
controls or unimpaired patients. Furthermore, they were able 
to define a threshold value of 39 Hz, which divided impaired 
from unimpaired patients.
Brain imaging
Currently, there is no established imaging modality or 
technique for the assessment of HE in clinical practice. The 
most widely utilized modality is magnetic resonance imag-
ing (MRI), with the most consistently reported sequence 
being MRS. MRS is a noninvasive technique used to 
determine the biochemical profile of a region of interest 
in vivo, thus giving information regarding the metabolic 
processes within that region. Several investigators have 
found consistent abnormalities in the MRS data from 
patients with HE.60
Other imaging modalities, such as PET, have been used 
in one case series,29 but have not been replicated by other 
groups. Similarly, techniques such as magnetoencephalogra-
phy have been described in the research setting,61 but world-
wide, very few centers have this equipment available.
Treatment of hepatic 
encephalopathy
No truly specific treatment for HE exists, as the exact patho-
genesis is unknown. The pharmacological treatments that are 
currently used in clinical practice are directed toward reduc-
ing the production and absorption of gut-derived ammonia.
Antibiotics
Antibiotics have been used to treat HE since the 1950s.62 
The nonabsorbable antibiotic, neomycin, reduces bacterial 
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ammonia production in the colon, by altering the normal 
gut flora. Neomycin is considered to be nonabsorbable, 
but a small percentage is absorbed, causing ototoxic and 
nephrotoxic side effects.63 Neomycin is now rarely used as 
rifaximin, which lacks these side effects, has become avail-
able more recently.
Rifaximin is a nonabsorbable derivative of rifamycin 
with a broad spectrum of activity against aerobic and 
anaerobic gram-positive and gram-negative organisms. 
It has a bioavailability of ,0.4%, and ∼97% of the drug 
is excreted in feces unchanged.64 These pharmacokinetic 
properties make it an attractive option for the treatment of 
HE. Clinical trials have compared rifaximin to lactulose 
or neomycin for treatment of HE. Rifaximin demonstrates 
a general trend toward better efficacy, compared with 
lactulose or neomycin, but long-term safety data are 
lacking.65 More recent papers have found rifaximin to be 
highly effective in the management of HE for the treat-
ment, maintenance of remission, and reduction in hospita-
lizations of chronic liver disease patients.66,67 However, 
the recent EASL/AASLD guidelines only recommend its 
use as an add-on therapy to lactulose, not as a first-line or 
sole treatment agent.1,2
Lactulose
Lactulose is a synthetic disaccharide taken orally, primarily 
used to treat constipation. It has been used to treat HE 
since the 1960s.68 When it reaches the colon, lactulose is 
metabolized by bacteria, predominantly to lactic acid. The 
fecal pH drops, favoring growth of lactose-fermenting 
organisms and suppressing organisms such as Bacteroides 
spp., which are ammonia formers. Additionally, it is thought 
that fecal acidity reduces ionization and subsequent absorp-
tion of ammonia. It has been demonstrated that lactulose 
at least doubles the colonic output of bacterial mass and 
soluble nitrogen, which can then no longer be absorbed.69 
Side effects of treatment include flatulence, diarrhea, and 
abdominal pain.
l-Ornithine l-aspartate
l-Ornithine l-aspartate (LOLA) is a treatment directed at 
removal of circulating ammonia. Ornithine promotes hepatic 
removal of ammonia by stimulating residual hepatic urea 
cycle activity through action of ornithine carbamoyltrans-
ferase and carbamoylphosphate synthetase. Additionally, 
ornithine and aspartate are both substrates for the urea 
cycle. In perivenous hepatocytes, ornithine and aspartate 
combine with α-ketoglutarate to produce GLU. GLU is used 
by skeletal muscle and brain to use ammonia, via the action 
of GS to produce GLN, reducing the amount of circulating 
ammonia.70 One study has demonstrated that intravenous 
LOLA ameliorates deleterious psychometric effects of GLN 
in Child’s grade B and C patients.71 A study of overt HE 
patients randomized to receive either oral LOLA or lactulose 
for 2 weeks found that while both agents reduced circulat-
ing ammonia levels, use of LOLA was also associated with 
significant improvements in mental status, psychometric 
parameters, and EEG activity.72 A meta-analysis of three 
randomized, controlled studies of the LOLA use in 212 
patients with HE concluded that LOLA is of benefit in overt 
HE, but the currently available data do not support its use 
in mHE.73
Nutritional therapies
vegetable-based protein
Contrary to previous reports, patients with HE should not 
be protein restricted. They are often in a catabolic state and 
require 1–1.5 g/kg of protein per day. Vegetable protein 
tends to be better tolerated than meat protein. Additionally, 
due to their high fiber content, vegetable proteins increase 
colonic motility, as well as improve fecal nitrogen output.74,75 
However, the clinical utility of a vegetable protein-based 
diet is limited by poor patient compliance and is not used 
routinely in many centers.
Prebiotics, probiotics, and symbiotics
Prebiotics are nondigestible food ingredients, stimulating 
growth of select colonic bacteria to improve host health, 
whereas probiotics are live microbial food supplement 
improving host gut microbial balance. Symbiotics are a 
combination of the two. A meta-analysis demonstrated that 
supplementing the diet with pre-, pro-, and symbiotics can 
lead to significant improvements in patients with MHE, 
suggesting that their inclusion may have clinical benefits. 
Furthermore, the supplements were well tolerated.76
Branched-chain amino acids
Administration of preparations high in BCAAs and low in 
aromatic amino acids (AAAs) is based on reducing transmis-
sion of AAAs across the blood–brain barrier, thus reducing 
production of false neurotransmitters, which can contribute 
to encephalopathy.75 Although BCAAs have been shown to 
improve both recovery and duration of hospital admissions,77 
a Cochrane systematic review found that BCAAs do not have 
significant beneficial effects on patients with HE. Studies 
involving BCAAs tend to be limited by short follow-up 
periods and poor methodological quality.78 Higher quality 
studies are required in this area.
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Orthotopic liver transplantation
Orthotopic liver transplantation (OLT) is the definitive 
treatment for HE arising in both acute liver failure (ALF) 
and chronic liver disease (CLD). However, its urgency 
depends on the cause and nature of liver failure. In patients 
with ALF who are progressing to cerebral edema and HE, 
an OLT is crucial to survival and urgent discussion with a 
liver transplant center is required to prevent deterioration to 
cerebral coning and brain death. In patients with CLD, HE 
tends to be chronic and fluctuating. It is considered to be 
one of the cardinal manifestations of decompensating liver 
disease. OLT in this group of patients tends to be determined 
according to need and prospective survival via established 
CLD criteria.79
Conclusion
HE is a neuropsychiatric syndrome, with symptoms exist-
ing on a continuum. Early recognition and management is 
imperative in optimizing outcome, particularly in the context 
of the timing of OLT. With the right treatment, most patients 
with overt HE can lead relatively normal lives with reason-
able neuropsychological function. Stability of underlying 
liver function and prompt treatment of precipitating factors, 
such as variceal bleeding and infections, is crucial to this. 
However, it should be remembered that in the acute setting, 
HE is the hallmark of acute liver failure and that urgent OLT 
may be required.
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